report publish week issu natur
somatogen research medic research council
laboratori molecular biolog cambridg england
describ new genet engin form hemoglobin
synthes bacteria
hemoglobin blood compon carri oxygen
tissu natur occur hemoglobin must chemic
modifi prevent break substanc
harm kidney improv abil releas
oxygen tissu said gari stetler somatogen vice
presid research develop chemic
process complex difficult control mr. stetler
said
describ natur articl somatogen newest
hemoglobin molecul need chemic modif thus
requir 12 fewer step compani previous
hemoglobin technolog requir chemic
modif new process allow greater control
product reduc cost mr. stetler said
somatogen believ unlik blood substitut
develop competitor use human anim blood
newest synthet blood wo limit suppli
sourc moreov compani hope consum
confid synthet product puriti sinc
use blood raw materi
somatogen hemoglobin current undergo earli human
test safeti efficaci test
approv process goe plan somatogen could readi
market blood substitut three year mr. stetler said
compani work blood substitut baxter
intern inc. deerfield ill. allianc pharmaceut
corp. san diego dnx corp. princeton n.j. biopur corp.
boston upjohn co. kalamazoo mich. major
invest market agreement number close
held compani
somatogen hot stock sinc went public $ 19
share august stock peak $ 50.50 januari
sinc cool rest biotechnolog group
close yesterday $ 30 25 cent over-the-count
trade
